Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Singh J, Cha E, Spahn J, Ou SI.
Kim DW, et al. Among authors: singh j.
JTO Clin Res Rep. 2022 Jun 25;3(8):100367. doi: 10.1016/j.jtocrr.2022.100367. eCollection 2022 Aug.
JTO Clin Res Rep. 2022.
PMID: 35875467
Free PMC article.